ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1355	National Cancer Institute	Html	en	Rectal Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of rectal cancer.	metastatic colorectal carcinoma 0.354846 hepatic colorectal metastases 0.223514 recurrent rectal cancer 0.223407 Engl J Med 0.263348 Ann Surg 0.278325 colorectal cancer risk 0.276481 asymptomatic colorectal cancer 0.241606 colorectal cancer surgery 0.262375 metastatic colorectal cancer 0.610251 adjuvant rectal cancer 0.215149 colorectal cancer 0.902264 randomized trial 0.206269 patients 0.22566 progressive colorectal cancer 0.233252 pT3-pT4 colorectal cancer 0.254826 Clin Cancer Res 0.224834 refractory metastatic colorectal 0.227594 malignant colorectal adenomas 0.207762 et al. 0.485182 familial colorectal cancer 0.266438 colorectal liver metastases 0.255119 measurable colorectal cancer 0.232282 Dis Colon Rectum 0.282416 PUBMED Abstract 0.3294	untreated metastatic colorectal 0.230109 colorectal hepatic metastases 0.221405 advanced colorectal cancer 0.352094 irinotecan-refractory metastatic colorectal 0.231657 Colorectal lung metastases 0.222615 advanced colorectal carcinoma 0.23983 recurrent colorectal cancer 0.262817 Surg Oncol 0.226556 colorectal cancer incidence 0.264939 colorectal cancer present 0.264636 colorectal cancer disparities 0.265307 colorectal cancer group 0.277657 colorectal cancer rates 0.265187 Colorectal Study Group 0.21517 Abstract 0.47664 colon cancer 0.223051 Clin Oncol 0.752938 Colorectal cancer follow-up 0.250811 liver-limited metastatic colorectal 0.225511 Oncol Biol Phys 0.206575 dutch colorectal cancer 0.274376 Clin Colorectal Cancer 0.277838 Cancer J Clin 0.227264 colorectal carcinoma metastases 0.224249	CLICK HERE
1369	National Cancer Institute	Html	en	Oral Cavity and Oropharyngeal Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for oral cancer.	oral examination 0.527557 primary screening tool 0.417249 squamous cell tumors. 0.370971 one-time oral cancer 0.520022 systematic oral cavity 0.508919 United States 0.382344 follow-up period 0.371029 sole randomized trial 0.365707 physical examination 0.446254 cause-specific mortality benefit 0.39145 opportunistic screening 0.371936 control group 0.369767 short follow-up period 0.359545 earlier stage cancers 0.419364 randomized controlled trials 0.375895 oral visual screening 0.601987 simple hand-held device 0.363139 oral cancer mortality 0.59501 premalignant lesions 0.420448 oral visual examination 0.580404 premalignant oral lesions. 0.561468 statistically significant result 0.355967 toluidine blue staining 0.36957 direct fluorescence visualization 0.371807	blue placebo dye. 0.359062 oral cancer 0.97737 oral/pharyngeal cancers 0.364948 oral surgery 0.457512 oral cancers 0.781555 15-year follow-up period 0.369337 overall annual incidence 0.409124 overall oral cancers 0.566597 routine examination 0.355451 screening group 0.361703 subclinical high-risk fields 0.375561 oral cancer examination. 0.562099 positive predictive values 0.349612 mortality hazard ratios 0.399552 population-based screening programs 0.456558 better health outcomes. 0.355075 oral cavity 0.532106 positive test rates 0.356123 periodic health examination 0.447578 oral cancer examination 0.728118 screening setting 0.362271 screening rounds 0.355833 cause–specific mortality rate 0.408751	CLICK HERE
1496	National Cancer Institute	Html	en	Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.	chronic idiopathic myelofibrosis 0.460932 -associated myelofibrosis 0.377277 primary myelofibrosis 0.76249 agnogenic myeloid metaplasia 0.307689 prognostic factors 0.222887 peripheral blood 0.22296 Mayo Clin Proc 0.241864 Lasho TL 0.217158 Br J Haematol 0.259671 blood cell transfusions 0.218297 Engl J Med 0.445409 red blood cell 0.333388 aforementioned prognostic systems 0.209417 JAK2-negative primary myelofibrosis 0.455533 Myelofibrosis Research 0.385033 peripheral blood myelophthisis 0.21294 Mesa RA 0.470382 myeloid metaplasia 0.871911 myeloproliferative neoplasms 0.310964 teardrop-shaped red blood 0.217055 myelofibrosis 0.915542 retrospective review 0.217962 Vera Study Group 0.206315 Abstract 0.596486	therapy 0.209486 patients 0.479624 Clin Oncol 0.364567 postoperative subcutaneous heparin 0.256357 Bone Marrow Transplant 0.217694 blood 0.376461 bone marrow 0.283097 thrombocythemia myelofibrosis 0.453249 blood cell survival 0.22308 peripheral blood granulocytes 0.213686 idiopathic myelofibrosis 0.478488 Asymptomatic low-risk patients 0.236666 Leuk Lymphoma 0.295111 International Prognostic Scoring 0.257794 clinical prognostic parameters 0.20507 high phlebotomy requirement 0.203305 post–essential thrombocythemia myelofibrosis 0.447393 allogeneic stem cell 0.353702 low-risk patients 0.238481 acute myelofibrosis 0.423026 blood cell transfusion 0.227086 et al. 0.52463 JAK inhibitors 0.215327	CLICK HERE
1751	National Cancer Institute	Html	en	Hospice Care	A fact sheet about hospice care, including insurance coverage.	palliative care share 0.4463 home health 0.436046 hospice programs 0.663338 hospice team 0.740949 specific care decisions 0.42786 hospice doctor 0.624846 spiritual support 0.408056 public health departments 0.391127 American Cancer Society 0.455655 hospice services 0.722561 home health aides 0.405139 state Medicaid office 0.402126 nursing care 0.391635 hospice medical director 0.768439 Hospice Association 0.649826 cancer care 0.409838 hospital business office 0.388593 life expectancy 0.408587 hospice team member 0.685192 special in-patient facilities 0.500987 Medicare website 0.415518 specific state locations 0.392604 government health insurance 0.402081 sheet Palliative Care 0.444628 state social services 0.40519	nursing homes 0.407681 end-of-life care 0.424373 health aide services 0.410795 hospice organizations 0.592662 Palliative Care Organization 0.507564 private insurance plans 0.399019 Hospice Net 0.623257 palliative care 0.604188 Medicare coverage 0.386456 national hospice 0.673933 regional home health 0.398589 national hospice programs 0.634262 hospice care 0.982488 local state welfare 0.391739 health insurance plans 0.419219 Medicare benefits 0.388255 hospice expenses 0.700651 insurance plans 0.503978 federal-state partnership program 0.389089 Medicare Hospice Benefits 0.695621 Medicare-certified hospice programs 0.660409 Respite Care page 0.429976 social work services 0.407475 free fact sheets 0.38648	CLICK HERE
1944	National Cancer Institute	Html	es	Síndromes cardiopulmonares (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el pecho. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, la efusión pleural maligna, la efusión pericárdica y el síndrome de la vena cava superior.	neoplásico pericárdico 0.570337 aurículas derecha 0.413336 siguientes procedimientos 0.476145 suficiente sangre 0.429294 disnea ayuda 0.428346 siguientes elementos 0.427349 PDQ Síndromes cardiopulmonares 0.420075 aurícula derecha 0.413308 pequeña cantidad 0.419135 líquido allí 0.447596 cuerpo.ampliar radiografía 0.576347 siguientes tipos 0.416182 síndromes cardiopulmonares 0.693009 rayos x 0.496155 suficiente oxígeno 0.422453 largo plazo 0.415907 menudo causa infecciones 0.442964 esclerosis pericárdica procedimiento 0.439765 obstructiva crónica 0.420705 pleural extracción 0.480399 vías respiratorias 0.858731	máxima presión 0.42053 National Cancer Institute 0.411568 pleural maligno 0.991379 vía respiratoria 0.496611 suficiente aire 0.455692 Ascitis Extracción 0.422054 siguientes tratamientos 0.411554 pequeñas vías respiratorias 0.434391 Pericardiotomía Procedimiento 0.427972 Instituto Nacional 0.420501 pericárdico extracción 0.450036 siguientes problemas 0.422606 siguientes factores 0.415522 Physician Data Query 0.44175 haz angosto 0.421283 linfangitis carcinomatosa terapia 0.435827 Pericardiectomía Cirugía 0.416216 mala nutrición 0.417318 insuficiencia cardíaca 0.522457 superior quimioterapia 0.453603 procedimiento ayuda 0.419009	CLICK HERE
1967	National Cancer Institute	Html	es	Tratamiento del cáncer de pene (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de pene.	siguientes procedimientos 0.765966 siguientes aspectos 0.663436 radiosensibilizadores ayuda 0.608332 estadio ii 0.653561 ganglio linfático centinela 0.99757 rayos x 0.61452 menor cantidad 0.630187 enlace drugs approved 0.616023 ondas sonoras 0.614903 National Cancer Institute 0.60451 siguientes riesgos 0.604706 papiloma virus 0.656514 únicos tratamientos 0.60726	Instituto Nacional 0.609778 Penile Cancer 0.60882 estadio iiia 0.623114 PDQ Tratamiento 0.608893 cuerpo esponjoso 0.725663 presente sección 0.608144 Physician Data Query 0.620917 siguientes sitios 0.675658 siguientes operaciones 0.617884 órgano masculino 0.616691 siguientes pruebas 0.65372 siguientes estadios 0.621615	CLICK HERE
2080	National Cancer Institute	Html	es	Exámenes de detección del cáncer de testículo (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de testículo.	estadios tardíos 0.651471 Visuals Online 0.570773 PDQ Exámenes 0.759721 Physician Data Query 0.918778 testículos.ampliar anatomía 0.643812 mejores tratamientos 0.631067 prevención revisa 0.590052	sistema urinario masculino 0.76274 glándulas sexuales masculinas 0.790025 información ayuda 0.600632 National Cancer Institute 0.62598 siguientes riesgos 0.575127 Instituto Nacional 0.738066	CLICK HERE
3605	National Cancer Institute	Html	en	Enhancing Drug Discovery and Development	The discovery and development of new therapeutic agents for cancer is essential for continued progress against the disease. Historically, NCI has played a vital role in cancer drug discovery and development, and, today, that role continues. Frequently, NCI’s drug development efforts focus on unmet needs that are not being adequately addressed by the private sector.	human tumor cell 0.493589 Developmental Therapeutics Program 0.373741 cell lines 0.756764 corresponding cancer types 0.401362 primary cancer cells 0.471158 drug discovery 0.918943 cell line panel 0.382826 long-term cell cultures 0.381121 drug screening 0.363881 development activities 0.393342 human cancer models 0.633791 human tumor samples 0.437784 precision medicine 0.432081 congressionally mandated initiative 0.360908 human cancer cell 0.54738 drug resistance 0.374751 tyrosine kinase inhibitor 0.365397 drug development efforts 0.451048 potential anticancer agents 0.404376 traditional cell lines 0.391913 parental tumors 0.388039 routine cancer care 0.38291 Cancer Treatment 0.353066 cancer cells 0.647891 cancer cell lines 0.473566	new human cancer 0.517038 cancer cell biology 0.425139 NCI Experimental Therapeutics 0.397544 tumor sections 0.354283 cell line screen 0.52167 largest cancer pharmacology 0.402164 cell culture techniques 0.37598 NCI-60 cell line 0.515114 drug discovery program 0.435482 NIH Clinical Center 0.354806 cancer stem cells 0.444759 anticancer drug discovery 0.568944 biologic agent discovery 0.381604 new therapeutic agents 0.383079 Cancer Chemotherapy National 0.425183 NCI’s anticancer 0.350161 clinical development resources 0.397358 NCI’s drug 0.370038 original tumor 0.350461 normal cell counterparts 0.370786 cancer drug discovery 0.678381 Human cancer cells 0.468312 multiple cell types 0.380725 tumor microenvironment 0.401449	CLICK HERE
3880	National Cancer Institute	Html	es	Extractos de muérdago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de los extractos de muérdago como tratamiento para personas con cáncer.	from mistletoe extract 0.31162 Cancer Res Clin 0.306787 mistletoe extracts 0.396569 album extract isorel 0.309539 Mistletoe extracts standardised 0.30709 viscum album 0.980886 galactoside-specific lectin from 0.335383 thionins from viscum 0.3152 muérdago i 0.308032 treated with viscum 0.312029 Cancer Res 0.31513 isolated from viscum 0.307496 extracto viscum album 0.308065 Viscum album agglutinin-induced 0.308373 with viscum album 0.33586 from viscum album 0.472392 beta-galactoside-specific lectin from 0.310754 Hajto T 0.314595 extract from viscum 0.316835 Viscum album enhancing 0.30854 patients with 0.307472 thionins from european 0.306901 Immunomodulatory Agents from 0.306741 viscum album extract 0.338924 viscum album l 0.601922	Mistletoe lectins as 0.306952 preparation from viscum 0.308802 Complement Ther Med 0.308742 tumor cell 0.31334 Mistletoe extracts standardized 0.30726 Beuth J 0.317637 mistletoe treatment 0.310143 lectin from 0.350339 derived from viscum 0.315008 In vitro effects 0.312037 Schaller G 0.307482 blood mononuclear cells 0.315901 subspecies viscum album 0.308835 lectin from viscum 0.322905 Gabius HJ 0.329931 Viscum album induces 0.316269 ml1 from viscum 0.307567 breast cancer 0.326075 Viscum album species 0.308916 plant lectin 0.306716 mistletoe lectins 0.449053 in vitro 0.456679 Hostanska K 0.309958 fermented extract from 0.30821	CLICK HERE
16162	National Cancer Institute	Html	en	New Therapies Are Changing the Outlook for Advanced Melanoma	An article about a host of new treatment options that have been produced in the last several years for patients with the skin cancer melanoma.	improved progression-free survival 0.366558 new therapies 0.351845 target BRAF proteins 0.357172 commonly used therapies 0.342946 BRAF inhibitor 0.43187 BRAF mutations 0.802264 Cancer Therapy Evaluation 0.357896 Overall survival results 0.381093 Dr. Schuchter 0.658164 overall survival 0.53856 clinical trials 0.561097 results 0.412771 median progression-free survival 0.364224 clinical trial 0.629151 median overall survival 0.359384 patients 0.941423 recent FDA-approved drugs 0.349384 tumor responses 0.376799 metastatic melanoma 0.378989 chemotherapy drug dacarbazine 0.34213 median survival 0.400006 melanoma specialist 0.389264 large clinical trial 0.469476 MEK inhibitor 0.413513	cancer cells 0.348742 Patient tumor samples 0.353483 skin-related side effects 0.386676 MEK inhibitor cobimetinib 0.40543 clinical trial participants 0.357541 BRAF-MEK inhibitor combination 0.3755 Dr. Streicher 0.487979 tumor cells 0.429743 checkpoint inhibitor 0.371337 small clinical trials 0.342687 drugs 0.41439 progression-free survival 0.707667 MEK inhibitors 0.605005 advanced melanoma 0.87481 PD-1 inhibitor 0.342866 recent clinical trials 0.345485 new treatment options 0.457424 tumors 0.426135 New Melanoma Therapies 0.48664 early-phase clinical trial 0.367414 Moffitt Cancer Center 0.358773 regulatory approval 0.407964 Pennsylvania Abramson Cancer 0.343564 skin cancer melanoma 0.49678	CLICK HERE